Drug intelligence / Profile preview

CAT-179

Development stage: Preclinical
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAT-179 is an allogeneic natural killer (NK) cell therapy product engineered to express a chimeric antigen receptor (CAR) targeting HER2, as well as interleukin-15 (IL-15) and transforming growth factor beta (TGFβ). This design aims to enhance NK cell persistence, proliferation, and anti-tumor activity while overcoming immunosuppressive signals in the tumor microenvironment. The primary indication under investigation for CAT-179 is renal cell carcinoma. As of the latest available information, development is at the preclinical stage[2].

Targets

IL15 (Interleukin 15)TGFB (GARP–latent transforming growth factor beta 1 complex)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CAT-179.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAT-179.

Explore the full profile